依革菩林是一种抗癌剂，它抑制微管的生长，连同曲贝特定和帕卓帕尼，已获批用于治疗晚期软组织肉瘤（STS）。然而，在多柔比星治疗失败后，这三种治疗方案中没有达成最佳二线治疗的共识。最近，关于依革菩林对乳腺癌的肿瘤微环境和免疫力的影响已被报道，并且已有报告称外周血免疫标志物是依革菩林疗效的预测因素，尽管这在STS中仍未得到验证。我们旨在评估在接受依革菩林治疗的STS患者中，各种外周血免疫标志物的预测价值。我们回顾了接受依革菩林治疗的STS患者的医疗记录，并检查了不同时间点的外周血免疫标志物是否能成为依革菩林治疗的预后因素。几种外周血免疫标志物与无进展生存期（PFS）显著相关，尤其是起始前的中性粒细胞与淋巴细胞比（NLR）（初始使用依革菩林之前的NLR）（P = 0.019）和第一次使用依革菩林后的第8天的绝对淋巴细胞计数（ALC）（ALC8D）（P = 0.037）。起始前的NLR（P = 0.001）与总生存期显著相关。起始前的NLR和ALC8D的组合确定了接受依革菩林治疗的STS患者的PFS。低起始前的NLR和高ALC8D的组合指标预测了接受依革菩林治疗的患者的生存以及L型肉瘤的组织学。尽管需要进一步验证，但这一发现将提供有价值的预后因素，帮助在STS患者多柔比星治疗失败后没有共识的情况下做出治疗决策。©作者（2023）。由牛津大学出版社出版。版权所有。要获得权限，请发送电子邮件至：journals.permission@oup.com。

eribulin, an anticancer agent that inhibits microtubule growth, along with trabectedin and pazopanib, has been approved for the treatment of advanced soft tissue sarcoma (STS). However, there has been no consensus on the optimal second-line therapy among these three agents following treatment failure with doxorubicin. Recently, the effects of eribulin on the tumor microenvironment and immunity have been reported in breast cancer, and peripheral blood immune markers have also been reported to be a predictor of eribulin efficacy, though this remains unverified in STS. We aimed to evaluate the predictive value of various peripheral blood immune markers in STS patients treated with eribulin.we retrospectively reviewed the medical records of STS patients treated with eribulin and examined whether peripheral blood immune markers at different time points could be prognostic factors for STS patients treated with eribulin.several peripheral blood immune markers were significantly associated with progression-free survival (PFS), specifically neutrophil-to-lymphocyte ratio (NLR) prestart (NLR before the initial administration of eribulin) (P = 0.019) and absolute lymphocyte count (ALC)8D (ALC on Day 8 of the first administration of eribulin) (P = 0.037). NLR prestart (P = 0.001) was significantly associated with overall survival. The combination of NLR prestart and ALC8D determined the PFS of STS patients treated with eribulin.the combined indicator of low NLR prestart and high ALC8D predicted the survival of patients treated with eribulin as well as the histology of L-sarcoma. Though further validation was needed, this finding would provide valuable prognostic factor that help treatment decision in the absence of consensus on the optimal second-line therapy following doxorubicin treatment in STS patients.© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.